SINOPHARM GROUP 1/5/O.N. (X2S1) — Cash Flow Reinvestment Rate
SINOPHARM GROUP 1/5/O.N. (X2S1) has a Cash Flow Reinvestment Rate of 0.12x as of December 2025, reinvesting €1.64 Billion (capex €1.62 Billion plus investments €21.76 Million) from operating cash flow of €14.14 Billion. See SINOPHARM GROUP 1/5/O.N. free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
SINOPHARM GROUP 1/5/O.N. Cash Flow Reinvestment Rate (2021–2025)
Historical reinvestment intensity for SINOPHARM GROUP 1/5/O.N. across 5 annual periods. For the full cash flow conversion analysis, see X2S1 cash generation efficiency.
Annual Cash Flow Reinvestment Rate for SINOPHARM GROUP 1/5/O.N. (2021–2025)
Year-by-year capital reinvestment analysis for SINOPHARM GROUP 1/5/O.N.. See SINOPHARM GROUP 1/5/O.N. (X2S1) flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.12x | €1.64 Billion | €14.14 Billion | €1.62 Billion | ▼ -32.2% |
| 2024 | 0.17x | €1.97 Billion | €11.55 Billion | €1.97 Billion | ▲ +24.4% |
| 2023 | 0.14x | €2.36 Billion | €17.17 Billion | €2.34 Billion | ▲ +13.9% |
| 2022 | 0.12x | €2.53 Billion | €20.96 Billion | €2.42 Billion | ▼ -54.7% |
| 2021 | 0.27x | €2.48 Billion | €9.31 Billion | €2.26 Billion | — |